New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export GILD’s income statement to Excel — free account
Gilead Sciences, Inc.
GILDHealthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.2%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
168.64
2.11
+1.27%
Follow GILD
Alert me
Gilead Sciences, Inc. 10-Q filed May 7, 2026
What changed
Part II, Item 1A, Risk Factors, against the 10-K filed Feb 24, 2026: 1 added · 3 removed · 39 modified; 1 moved without change